Summary

Eligibility
for people ages up to 29 years (full criteria)
Location
at UC Davis UCSF
Dates
study started

Description

Summary

This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more tumor cells.

Official Title

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

Details

Keywords

Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Neoplasms, Wilms Tumor, Dactinomycin, Cactinomycin, Cyclophosphamide, Doxorubicin, Liposomal doxorubicin, Etoposide, Vincristine, Etoposide phosphate, Podophyllotoxin, 3-Dimensional Conformal Radiation Therapy, Doxorubicin Hydrochloride, Vincristine Sulfate Liposome

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Children's Oncology Group
Links
Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
ID
NCT00379340
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 395 people participating
Last Updated